Citation

Price RB, Nock MK, Charney DS, Mathew SJ. Biol. Psychiatry 2009; 66(5): 522-526.

Affiliation

Department of Psychiatry, Mount Sinai School of Medicine, New York; Department of Psychology, Rutgers, the State University of New Jersey, Piscataway, New Jersey.

Copyright

(Copyright © 2009, Elsevier Publishing)

DOI

10.1016/j.biopsych.2009.04.029

PMID

19545857

PMCID

PMC2935847

Abstract

BACKGROUND: Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between concepts, may have utility in suicide assessment. METHODS: Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 hours before and 24 hours following a single subanesthetic dose of intravenous ketamine. Ten patients also completed IATs assessing implicit suicidal associations at comparable time points. In a second study, nine patients received thrice-weekly ketamine infusions over a 12-day period. RESULTS: Twenty-four hours after a single infusion, MADRS-SI scores were reduced on average by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion. Implicit suicidal associations were also reduced following ketamine (p = .003; d = 1.36), with reductions correlated across implicit and explicit measures. MADRS-SI reductions were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42). CONCLUSIONS: These preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.

Language: en